Professor Andrew Hughes MA MB ChB MRCP FFPM PhD PGDip

Co-lead on Experimental Therapeutics in support of BRC

MCRC Steering Group member; architect in Human Tissue Bank and Pre-operative Trials. Co-supervisor of CRUK and Wellcome Clinical fellowship schemes; and Co-Director of MRes in Translational Medcine. Member of CRUK BIDD funding committee and MRC DPFS panel

Dual appointment with AstraZeneca- head of early clinical oncology development

• American Society of Clinical Oncology
• Fellow Faculty Pharmaceutical Physicians
• American Association of Cancer Research
• British Pharmacological Society
• CRUK BIDD committee member 
• Board Member, ABPI Cancer group
• MRC DPFS committee member

• Biomarkers in cancer research
• Target linkage in cancer research
• Early clinical trials of novel cancer treatments

• Phase O trials
• Microdosing
• eIND studies
• Biomarker qualification

• MRes Translational Medicine
• PhD clinical fellowships with CRUK and Wellcome

Professor Andrew Hughes leads the early clinical development group for Cancer based at AstraZeneca, Alderley Park, Cheshire. This role involves overseeing the translational research programmes supporting over 30 products in late phase discovery and early clinical development; and the early clinical trials of novel cancer candidate drugs. He graduated with double first in medical sciences at Cambridge, spending 3 years as a Tutor in Physiology and Bye-fellow of Downing College, Cambridge, whilst completing a PhD in behavioural neuroendocrinology in the Department of Anatomy. He subsequently practised general clinical medicine in Manchester’s teaching hospitals in the UK, joining Zeneca in 1994 from being a registrar in Cardiology, and until recently continued with clinical work. Within the industry, he has had responsibilities on the corporate pain control drug development board and in setting the limits of human exposure based on existing pre-clinical and clinical data for all development products. Since 2001 he has been accountable for the early phase clinical development of AstraZeneca’s oncology compounds in volunteers and patients, and has been clinical investigator on over 150 clinical trials. He is approved by the Resuscitation Council (UK) as a director in Advanced Cardiac Life Support, and regularly teaches health professionals in ACLS. During 2002-3 he served on the board of the Faculty of Pharmaceutical Medicine, UK; and has the responsibility for the clinical pharmacology revision module for those physicians sitting the Diploma of Pharmaceutical Medicine. He is a member of the board of NCRI, on the editorial committee for Annals of Oncology and on the Steering Committee for the FDA Biomarkers Consortium. In November 2006, he was appointed to a chair of Translational medicine at the University of Manchester, UK.

• MA Anatomy, Cambridge
• PhD Neurosciences, Cambridge
• MB ChB (Hons), Manchester
• MRCP, Royal College Physicians, London
• FFPM, Royal College Physicians, London
• PGDip Clinical Pharmacology, Guildford

Professor Caroline Dive

Professor Malcolm Ranson

Professor Noel Clarke

Professor Tim Illidge

Dr Fiona Blackhall

Professor Ian Stratford

Dr Philip Padfield

Professor Nic Jones

Professor John Radford

Professor Gordon Jayson